Europe Part 3# Entrance wallet in Biotech! IntelliPharmaCeutics International (IPCI $)
My LAST POST TODAY LIMITED TO 3 per Day Sorry
For once we begin the analysis technique much vaunted by all but as you can see often on biotech stocks counts up to a certain point.
I always keep under control regardless of the title and then you'll understand why by reading the article but despite not having high trade (me has always been so in view of the few shares outstanding) right AT me buy back the title.
Just looking at the chart we can see that the actions of the titoto IntelliPharmaCeutics International Inc. (IPCI $) are holding above various moving averages. I think investors are taking positions ahead of important events catalysts FDA.
It was recently published a comprehensive analysis of Brean Murray, Carret & Co. investment bank dedicated to small cap and emerging growth companies and has recently published a BUY rating and a target price of $ 7 per IntelliPharmaCeutics.
For the uninitiated, the Canadian company now has a number of ANDA under review by the FDA. For the uninitiated are the ANDA Abbreviated New Drug Application or requests for approvals of generic drugs, which as you know is a big savings for patients and families.
The Company develops both ANDA products and new drugs through the New Drug Application (NDA) 505 (b) (2) regulatory pathway. You will understand that this strategy for a small business could be a winner.
So summarizing the ANDA we have not given certain but doing the count when there have been more or less we can do the calculations. That said expect a response from the FDA on:
Effexor, ANDA filed in January 2010 expect an answer at the end of the year of 2014.
Protonix ANDA has been accepted by the FDA in June 2010 with a launch possible at the time of FDA approval.
Glucophage XR ANDA has been accepted by the FDA in August 2010 with a launch possible at the time of the approval of the FDA, which represents another potential catalyst for approval during 2H14 or early next year.
Lamictal XR and Seroquel XR are under ANDA also presented to them in February 2011 and September 2011, but we will have to wait of course.
Rexista rather not be presented as ANDA but as 505 (2) via the NDA as a new formulation of a drug already approved are coming the second set of data from the phase 2 of the Rexista, and it should be the beginning of a phase 3 during 2h14
So what are the risks of buying the title ?. Like all small biotech companies are increasingly at risk dilution but the past has taught us that the company has always sought in every way to do it as little as possible looking more 'strategic partners rather than issuing equity. these ANDA in the case of positive responses from FDA could lead to some kind of agreement for sale. What has weighed on the company this year? 's slow responses by FDA generics division, but I think at this point we are at a turning point.
AI
